Bacteriology

Global Human Microbiome Therapeutics Markets, 2019-2027 Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Microbiology, Bacteriology, Organisms, Environmental microbiology, Bacteria, Human microbiota, Microbiota, Pharmacomicrobiomics

The "Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.
  • What are the major market drivers, challenges, and opportunities in the global human microbiome therapeutics market?
  • What was the market value of the leading segments and sub-segments of the global human microbiome therapeutics market?
  • Which region carries the potential for the significant expansion of key companies for human microbiome therapeutics market?

Revenue Forecasts for the Top Twelve Probiotics Manufacturers, 2019-2024

Retrieved on: 
Friday, November 1, 2019
Bacteriology, Digestive system, Probiotic, Dietary supplement, Biotic

It profiles the top 12 companies of the probiotics industry and explores the underlying technologies driving the industry's growth.

Key Points: 
  • It profiles the top 12 companies of the probiotics industry and explores the underlying technologies driving the industry's growth.
  • The scope also includes analysis of the probiotics market based on ingredients, applications, end-users, functions, and regional markets.
  • Revenue forecasts for 2019 through 2024 are provided at the global level for the above segments.
  • The probiotics market is segmented into five categories:
    By Application: Food and Beverages, Dietary Supplements and Animal Feed.

Global Probiotics Market Size, Share & Trends Analysis Report, 2019-2025: Key Players are Arla Foods, BioGaia, Danone, General Mills, Danisco and Lallemand

Retrieved on: 
Thursday, October 31, 2019
Medical specialties, Digestive system, Probiotics, Food and drink, Medicine, Bacteriology, Danone, BioGaia, Bifidobacterium animalis

The considerable production and consumption of probiotics is complemented by innovations in probiotics by key players, most notably in countries such as China, Japan, and India.

Key Points: 
  • The considerable production and consumption of probiotics is complemented by innovations in probiotics by key players, most notably in countries such as China, Japan, and India.
  • Following the growing demand for probiotics, key market participants have been investing in R&D activities to develop efficient probiotic strains.
  • Product innovation, mergers & acquisition, and portfolio expansion are some of the key strategies deployed by the key players.
  • Some of the key market players are Arla Foods, Inc.., BioGaia AB, Danone, Chr.

Global Prebiotic Association Adds Five New Members

Retrieved on: 
Thursday, October 31, 2019
Oligosaccharides, Bacteriology, Digestive system, Branches of biology, Biological evolution, Biology, Prebiotic, Galactooligosaccharide, Abiogenesis

SPRING, Texas, Oct. 31, 2019 /PRNewswire/ -- Today the Global Prebiotic Association (GPA), the worldwide resource for prebiotic education, insights and awareness building, announced the addition of five new members.

Key Points: 
  • SPRING, Texas, Oct. 31, 2019 /PRNewswire/ -- Today the Global Prebiotic Association (GPA), the worldwide resource for prebiotic education, insights and awareness building, announced the addition of five new members.
  • "These new members also expand our scope of prebiotic types we represent by adding polyphenols, lactulose and galacto-oligosaccharides."
  • The Global Prebiotic Association is comprised of scientifically-validated prebiotic ingredient manufacturers, brand holders, retailers and service companies.
  • For more information on prebiotics and the Global Prebiotic Association, please visit www.prebioticassociation.org .

Study Shows Human Milk Oligosaccharides Significantly Improve IBS Symptoms

Retrieved on: 
Wednesday, October 30, 2019
Branches of biology, Medical specialties, Health, Digestive system, Microbiology, Breastfeeding, Bacteriology, Environmental microbiology, Human milk oligosaccharide, Gastrointestinal tract, Gut flora, American College of Gastroenterology

CHICAGO, Oct. 30, 2019 /PRNewswire/ -- A landmark study presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting is shedding new light on how compounds that are structurally identical to human milk oligosaccharides (HMOs) can significantly improve IBS symptoms within four weeks.

Key Points: 
  • CHICAGO, Oct. 30, 2019 /PRNewswire/ -- A landmark study presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting is shedding new light on how compounds that are structurally identical to human milk oligosaccharides (HMOs) can significantly improve IBS symptoms within four weeks.
  • ACG reports that while an estimated 10-15% of adults in the U.S. suffer from IBS, only about half have been diagnosed.
  • In recent years, research has linked IBS with imbalances in gut microbiota, a "community" of microorganisms, or bacteria, found in the gastrointestinal (GI) tract.
  • Glycom is a global biotechnology company dedicated to the scientific, clinical and commercial development of human milk oligosaccharides (HMOs) for a broad range of health applications.

Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award

Retrieved on: 
Wednesday, October 30, 2019
Biotechnology, Science, Health, Research, Branches of biology, Bacteriology, Microbiology, Organisms, Environmental microbiology, Bacteria, Human microbiota, Microbiota

Vedanta Biosciences , a clinical-stage company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, is pleased to announce that its co-founder and CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center in the Life Science Business category.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, is pleased to announce that its co-founder and CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center in the Life Science Business category.
  • This award honors the outstanding contributions of immigrant entrepreneurs who have built successful businesses in Massachusetts, including their impact on the innovation economy and service to local neighborhoods.
  • Vedanta Biosciences has benefited enormously from access to a global talent pool in Massachusetts, where entrepreneurial and skilled immigrants from around the world are welcomed.
  • Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria.

General Automation Lab Technologies and CosmosID Launch Microbiome Challenge Program

Retrieved on: 
Tuesday, October 29, 2019
Software, Biotechnology, Nanotechnology, Pharmaceutical, Health, Data management, Technology, Genetics, Branches of biology, Microbiology, Bacteriology, Organisms, Bacteria, Microbiota, Workflow, Human Microbiome Project

General Automation Lab Technologies (GALT) and CosmosID today announced the launch of a new scientific challenge program to award a complete microbiome characterization workflow to one entrant.

Key Points: 
  • General Automation Lab Technologies (GALT) and CosmosID today announced the launch of a new scientific challenge program to award a complete microbiome characterization workflow to one entrant.
  • Manoj Dadlani, CEO of CosmosID, commented: Scientific competitions have a long and successful history of inspiring exciting new approaches, and we believe this program will do the same for the microbiome field.
  • Researchers may enter the challenge program by submitting a short abstract proposing a project that would make use of the GALT and CosmosID technologies.
  • General Automation Lab Technologies (GALT), a privately held company based in Silicon Valley, is a leading developer of next-generation cultivation platforms for microbiome research and microbial product development, addressing high-impact markets including human health, agriculture, environmental science, and microbial products for industrial use.

C.DIFF BREAKTHROUGH: Genetic Lab to Share Gut Microbiome Discovery at ACG 2019

Retrieved on: 
Monday, October 28, 2019
Medical specialties, Branches of biology, Bacteriology, Environmental microbiology, Microbiology, American College of Gastroenterology, Gut flora, Microbiota, Gut, Microorganism

They will present a validated, verified, and reproduced C.diff Assay at The American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting on Monday, Oct. 28, 2019 in San Antonio.

Key Points: 
  • They will present a validated, verified, and reproduced C.diff Assay at The American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting on Monday, Oct. 28, 2019 in San Antonio.
  • "This data will change healthcare and make us more aware of our gut microbiome," said Dr. Sabine Hazan-Steinberg, CEO and Founder of Progenabiome.
  • Progenabiome will present this groundbreaking discovery at ACG 2019 (Poster 1027 / Booth 1931) and the 7th Annual International C.diff Conference November 6-7, 2019 in St. Louis.
  • Progenabiome's Mission: to better understand, prevent, and treat diseases by analyzing specific genetic codes of 40 trillion gut microbes.

Beyond Air™ Schedules Fiscal Second Quarter 2020 Financial Results Conference Call and Webcast

Retrieved on: 
Thursday, October 24, 2019
Medical specialties, Medicine, Health, Bacterial diseases, Tuberculosis, Bacteriology, Infectious causes of cancer, Nontuberculous mycobacteria, Bronchiolitis, Bronchiole, Respiratory tract, Mycobacterium

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.

Key Points: 
  • Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.
  • The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.
  • The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care.
  • Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM).

Sun Genomics Launches Breakthrough Solution To Deliver Personalized Probiotics In Only Six Weeks

Retrieved on: 
Thursday, October 24, 2019
Branches of biology, Biology, Life sciences, Genomics, Bacteriology, Digestive system, Biotechnology, Probiotic, DNA sequencing, Omics

Sun Genomics Flore is a breakthrough for anyone concerned with improving their and their familys health.

Key Points: 
  • Sun Genomics Flore is a breakthrough for anyone concerned with improving their and their familys health.
  • Sun Genomics Flor precision probiotics solution is based on a patented two-step process, incorporating DNA sequencing and the micro-manufacturing of custom probiotics to address the specific gut health issues identified in the analysis.
  • Sun Genomics is a first-of-its-kind, customized probiotics startup thats mission is to improve overall health through personalized science.
  • By using DNA sequencing, Flor formulates the right probiotics for overall health and delivers it directly to the customers door.